Bone marrow biopsy says 82% blasts and positive for Philadelphia chromosome (BCR-ABL1). What does this mean for treatment?
I am 29 years old. Blood routine showed TLC 88,000 and platelets 24,000. Bone marrow aspirate confirmed B-Acute Lymphoblastic Leukemia with 82% blasts, and cytogenetics found t(9;22) BCR-ABL1 Philadelphia positive. My doctor is talking about Tyrosine Kinase Inhibitors and Stem Cell Transplant. Can you explain in simple terms?
Dr. Vinod Raina (MBBS, MD, FRCP (London))
Key Concepts You Need to Understand:
1. The Philadelphia Chromosome: A genetic swap between chromosomes 9 and 22 creates an abnormal fusion protein called BCR-ABL1, which acts like an engine stuck in full-throttle, causing your bone marrow to produce immature white cells (blasts).
2. Targeted TKIs (The Silver Bullet): Instead of relying solely on heavy chemo, we now have targeted tablets called TKIs — specifically Dasatinib or Ponatinib. They directly turn off the BCR-ABL1 fusion engine.
3. The Modern Treatment Plan:
- Phase 1 (Induction): TKI (Dasatinib) combined with low-intensity chemo or modern immunotherapy (Blinatumomab) to drive blasts from 82% down to 0% (Complete Remission and Minimal Residual Disease negativity).
- Phase 2 (Consolidation & Transplant): Because you are young (29 years), once in deep remission, an Allogeneic Hematopoietic Stem Cell Transplant (BMT) from a matched sibling or unrelated donor offers the highest cure probability.
Keep high spirits; with contemporary targeted therapy, remission rates exceed 95%.